ADC analytics FAQs: Answering the most common questions about ADC characterization

Aug 14, 2026 | Biopharma, Blogs | 0 comments

Antibody-drug conjugates (ADCs) have emerged as one of the fastest-growing classes of biotherapeutics, combining the targeting specificity of monoclonal antibodies with the potency of cytotoxic payloads. However, this unique architecture also introduces significant analytical complexity. From drug-to-antibody ratio (DAR) distributions and charge variants to conjugation sites and structural modifications, ADCs present multiple, interconnected sources of heterogeneity that must be understood to ensure product quality and performance.

In this FAQ, we answer some of the most common questions about ADC characterization and explore how modern analytical strategies can help transform complex data into actionable insight.

What makes ADC characterization more challenging than monoclonal antibodies?

ADCs are structurally more complex because they combine an antibody, linker, and cytotoxic payload. Each component introduces variability, resulting in overlapping sources of heterogeneity such as DAR distributions, charge variants, and structural modifications. These attributes must be analyzed together to fully understand product quality.

Why is it difficult to interpret ADC heterogeneity using traditional workflows?

Conventional analytical approaches typically measure attributes like DAR, charge, or size independently. While these methods provide useful data, they often cannot explain how these attributes are related or what structural changes are driving observed differences. This results in fragmented datasets that are difficult to interpret in a unified way.

Is measuring DAR or charge variants enough to characterize an ADC?

No. DAR and charge profiling are critical measurements, but they do not provide complete structural insight on their own. For example, DAR distribution shows how much payload is attached, but not which molecular species are present. Similarly, charge variants indicate change but may not reveal the structural cause without additional analysis.

What is a multi-attribute approach to ADC analysis?

A multi-attribute approach integrates multiple analytical techniques to provide a more complete understanding of ADC structure. These workflows combine:

  • High-resolution separation (e.g., CE, icIEF-UV/MS, LC)
  • Molecular identification (e.g., mass spectrometry)
  • Structural characterization (e.g., peptide mapping, fragmentation)

Together, these techniques enable scientists to correlate heterogeneity across multiple levels of analysis.

How is CE used in ADC characterization?

Capillary electrophoresis (CE) provides high-resolution separation of ADC variants, making it particularly effective for resolving charge heterogeneity and structural differences. Techniques such as CE‑SDS can also assess subunit integrity, detecting fragmentation and incomplete conjugation. These methods are highly reproducible and well suited for both development and QC workflows.

What role does mass spectrometry play in ADC analysis?

Mass spectrometry enables detailed molecular characterization of ADCs, including:

  • Identification of proteoforms
  • Determination of DAR species
  • Detection of low-abundance variants
  • Confirmation of sequence
  • Characterization of isomers

When combined with separation techniques, MS provides the structural context needed to interpret heterogeneity and link it to product quality.

Why is advanced fragmentation important for ADC characterization?

Advanced fragmentation techniques, such as electron-activated dissociation (EAD), allow for precise localization of payload attachment sites and post-translational modifications. These approaches preserve labile features that may be lost with conventional fragmentation, enabling more accurate structural characterization.

How can ADC analytics support comparability and process development?

By linking analytical results to molecular identity, multi-attribute workflows provide clearer insight into how structural changes impact critical quality attributes (CQAs). This supports:

  • More confident comparability assessments
  • Improved understanding of process-induced variability
  • Better alignment of analytical methods from development to QC

 

Want to discuss your ADC workflow?
Connect with a SCIEX expert to explore analytical strategies for charge heterogeneity, DAR analysis, payload localization, structural characterization, and quantitative ADC workflows.
Request more info >

Why traditional MS/MS falls short for ADCs and how electron-activated dissociation (EAD) changes the equation

Antibody-drug conjugates (ADCs) are among the most promising—and analytically demanding—modalities in biopharma today. By combining large, heterogeneous antibodies with chemically labile payloads and linkers, ADCs introduce a level of structural complexity that challenges conventional analytical workflows. It also poses the challenge that the very features you need to measure are often the easiest to lose during analysis.

Six benefits of remote support every laboratory should know

Imagine having a tech expert at your fingertips to solve computer issues or a fitness trainer guiding you through workouts from the comfort of your home. In today’s fast-paced world, the ability to provide and receive service and support remotely is no longer a luxury but a necessity. Whether it’s troubleshooting a software issue, repairing a device, offering customer assistance, or enjoying the convenience of telehealth as a private individual, remote capabilities have revolutionized how businesses operate and how individuals get help

The costly consequences of unplanned downtime

Unplanned downtime is a formidable adversary that businesses across various industries strive to minimize. Defined as the unexpected interruption of regular operations, unplanned downtime can wreak havoc on productivity, profitability and customer satisfaction. In this article, we delve into the causes of unplanned downtime, its far-reaching consequences and strategies to mitigate its impact.

Posted by

Roxana has over 15 years of experience in sales and marketing roles in the MS community. As Senior Global Marketing Manager for protein therapeutics at SCIEX, she specializes in communicating innovations in MS and CE-based workflows to the biopharma community.

0 Comments

Submit a Comment

Pin It on Pinterest

Share This

Share this post with your network